# Weight-Loss Jabs 2026: Cost, Comparison and the Honest Picture on Wegovy, Mounjaro and Ozempic

In Germany in 2026, a weight-loss jab costs you roughly 104 to 482 euros a month out of pocket, depending on the drug and dose. Ozempic runs about 104 to 200 euros, Wegovy about 172 to 277 euros, Mounjaro about 206 to 482 euros. Statutory health insurance pays none of it for weight loss, because these have counted as excluded lifestyle drugs under Section 34 SGB V since 2004. Budget honestly for the long term, since stopping usually brings most of the weight back.

In Germany in 2026 a weight-loss jab costs you roughly 170 to 480 euros a month out of pocket, and statutory health insurance does not pay for it. Here is the honest comparison: what each drug does, what it costs, where the risks are, and why stopping almost always triggers weight regain.

## On this page

- What does a weight-loss jab cost in Germany in 2026?
- Ozempic, Wegovy or Mounjaro: what is the difference?
- How well does tirzepatide really work? (SURMOUNT-1 and beyond)
- What side effects and risks does the weight-loss jab have?
- Who is the weight-loss jab for, and who is it not for?
- Keeping muscle on GLP-1: how do you lose fat instead of muscle?
- What comes next? Retatrutide and the triple agonists

## FAQ

- What does the weight-loss jab cost per month in Germany in 2026?
- Does statutory health insurance pay for the weight-loss jab?
- Is it true that insurance reimburses the weight-loss jab from 15.06.2026?
- Which is stronger, Mounjaro or Wegovy?
- Can I take Ozempic to lose weight because it is cheaper?
- Does the weight-loss jab cause thyroid cancer?
- What happens when I stop the weight-loss jab again?
- Do I lose muscle instead of fat with the weight-loss jab?

## Sources

- apodiscounter (Ratgeber Abnehmen). (2026). Abnehmspritze Kosten 2026. apodiscounter.de. https://www.apodiscounter.de/ratgeber/abnehmen/abnehmspritze/kosten
- fitfursleben.de. (2026). Wegovy Preis 2026 in Deutschland: Kosten pro Monat ab 172 Euro. fitfursleben.de. https://www.fitfursleben.de/wegovy/preis
- Sozialgesetzbuch Fuenftes Buch (SGB V). (2024). Paragraf 34 SGB V: Ausgeschlossene Arznei-, Heil- und Hilfsmittel. dejure.org. https://dejure.org/gesetze/SGB_V/34.html
- Gemeinsamer Bundesausschuss (G-BA). (2024). G-BA vollzieht den gesetzlichen Verordnungsausschluss fuer das Abmagerungsmittel Wegovy nach. g-ba.de. https://www.g-ba.de/presse/pressemitteilungen-meldungen/1170/
- beck-aktuell (Redaktion). (2025). Kein Anspruch auf Kostenuebernahme fuer Lifestyle-Medikament Mounjaro (SG Darmstadt S 13 KR 375/24). beck-aktuell.de. https://rsw.beck.de/aktuell
- rechtslupe.de; gesundheitsrecht.blog. (2025). Abnehmspritze und Krankenkasse 2026: Lifestyle-Medikament-Rechtsprechung. rechtslupe.de. https://www.rechtslupe.de
- diabe.de. (2026). Wegovy kaufen Deutschland: Verfuegbarkeit, Preis und Rezept 2026. diabe.de. https://diabe.de/wegovy-kaufen-deutschland-verfuegbarkeit
- comparative review (ScienceDirect). (2025). GLP-1 Receptor Agonists: Clinical Guide to Semaglutide and Tirzepatide; comparative review. Pharmacological Research. https://www.sciencedirect.com/science/article/pii/S0753332225009254
- Aronne LJ, et al.; SURMOUNT-5 Investigators. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2416394
- Novo Nordisk / European Medicines Agency (EMA). (2024). Wegovy (semaglutide) Summary of Product Characteristics / EPAR Product Information. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
- European Medicines Agency (EMA). (2024). Wegovy EPAR Product Information (dose-escalation table and 2.4 mg maintenance dose). European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
- European Medicines Agency (EMA) / Eli Lilly. (2024). Mounjaro (tirzepatide) EPAR / Product Information. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
- Chemist4U. (2026). The Mounjaro Dosing Schedule and Titration Calendar. chemist-4-u.com. https://www.chemist-4-u.com
- Jastreboff AM, et al.; SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
- review (PubMed Central PMC11576767). (2024). Efficacy and Safety of Tirzepatide for Obesity: a review collating SURMOUNT-1 responder and adverse-event detail. PMC11576767. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576767/
- Wilding JPH, et al.; STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2032183
- Frias JP, et al.; SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2107519
- He L, et al.. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2022.0338
- Wen J, et al.. (2025). Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70113
- U.S. Food and Drug Administration (FDA). (2022). Thyroid C-cell tumor (MTC/MEN2) boxed-warning basis: FDA prescribing labels for Ozempic and Mounjaro plus thyroid-risk reviews. accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s020lbl.pdf
- Tinsley GM, Nadolsky S. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. SAGE Open Medical Case Reports. https://doi.org/10.1177/2050313X251388724
- Cleveland Clinic Health Essentials. (2024). Ozempic Face: facial volume loss from rapid weight loss (clinical explainer). health.clevelandclinic.org. https://health.clevelandclinic.org/ozempic-face
- Wilding JPH, et al.. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14725
- SURMOUNT-1 Investigators (substudy). (2025). Changes in body composition following tirzepatide (SURMOUNT-1 body-composition substudy). substudy of SURMOUNT-1 (NEJM). https://www.ncbi.nlm.nih.gov/pubmed/?term=SURMOUNT-1+body+composition
- Jastreboff AM, et al.. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2301972

_Full guide: https://longevity-germany.com/en/guide/abnehmspritze-kosten-vergleich_

---

_Canonical: https://longevity-germany.com/en/guide/abnehmspritze-kosten-vergleich · Part of Longevity Cities · Updated 2026-06-14_